Contents
Key findings
- 1A peptide is a chain of roughly 2 to 50 amino acids; longer chains are called proteins. The boundary is conventional, not biological.
- 2Your body makes hundreds of peptide hormones and signalling molecules — insulin, GLP-1, oxytocin, growth hormone-releasing hormone — which is why so many peptide drugs are engineered copies of natural signals.
- 3More than 80 peptide drugs are FDA-approved. Semaglutide and tirzepatide are peptides with some of the strongest trial evidence in modern medicine.
- 4"Peptide" is a chemical class, not a level of evidence. BPC-157 and semaglutide are both peptides; one has tens of thousands of trial participants and the other has none in a controlled efficacy trial.
- 5"Research peptides" sold online are the same molecules regulators evaluate — but the products themselves are unregulated, and their identity and purity are not verified.
Evidence level
This is a definitional article. The chemistry of peptides is settled science; the evidence for any particular peptide's effects must be assessed one claim at a time.
Regulatory status
"Peptides" as a category has no single regulatory status. Individual peptides range from FDA-approved drugs to unapproved substances; each profile on this site states its own status.
"Peptide" has become a marketing word. It is used to sell everything from a Nobel-prize-adjacent diabetes drug to unlabelled vials shipped from overseas. Understanding what the term actually means — and what it doesn't — is the first step to reading any peptide claim critically.
The short answer
A peptide is a short chain of amino acids joined by peptide bonds. Two amino acids make a dipeptide; a few dozen make an oligopeptide or polypeptide; once the chain gets long enough to fold into a stable three-dimensional structure — conventionally around 50 amino acids — we call it a protein. The FDA, for its own regulatory purposes, draws the line at 40 amino acids: anything at or below that is a peptide reviewed as a drug, anything above is a protein regulated as a biologic[1].
That is the whole definition. It says nothing about what a peptide does, whether it works, or whether it is safe. Insulin is a peptide. So is the artificial sweetener aspartame (a dipeptide). So is BPC-157. Grouping them tells you about their chemistry, not their evidence.
Where peptides come from
Your body runs on peptide signals. Insulin, glucagon, GLP-1, oxytocin, vasopressin, growth hormone-releasing hormone, endorphins and dozens of other hormones and neurotransmitters are peptides. They tend to be potent, specific and short-lived — cleaved by enzymes within minutes — which makes them excellent signals and, in their natural form, poor drugs.
Most peptide drugs are therefore engineered versions of natural signals: the sequence is modified to resist enzymes, and chemical groups are attached to slow clearance. Semaglutide is human GLP-1 with two amino-acid changes and a fatty-acid chain that binds albumin, stretching its action from minutes to a week. Tesamorelin is GHRH with a stabilising group on one end. Bremelanotide is a cyclised metabolite of a melanocortin analogue.
Other peptides are fragments: BPC-157 is described as a piece of a stomach protein; TB-500 is marketed as a piece of thymosin beta-4. Others still are food: collagen peptides are what you get when you chop collagen into short pieces with enzymes.
Peptides as drugs: a large, real category
More than 80 peptide drugs have been approved by the FDA, and dozens more are in late-stage development[2]. Peptides sit between small-molecule drugs (aspirin, statins) and large biologics (antibodies) in size, and share some strengths of each: they can be highly selective for their targets like biologics, while being cheaper to make and sometimes easier to modify than antibodies. Their weaknesses are pharmacokinetic — most cannot be taken by mouth intact and are cleared quickly — which is why so much peptide engineering goes into extending half-life.
The incretin drugs illustrate how strong peptide evidence can be. Semaglutide's STEP 1 trial randomised nearly 2,000 adults and found about 15% mean weight loss over 68 weeks[3]; its cardiovascular outcomes trial randomised over 17,000. By any standard, that is established evidence.
Study details: Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
- Study type
- Randomised, double-blind, placebo-controlled phase 3
- Population
- Adults with overweight or obesity, without diabetes
- Sample size
- 1961
- Primary result
- Mean weight loss 14.9% vs 2.4% placebo at 68 weeks.
- Year
- 2021
- Source
- New England Journal of Medicine(link not yet independently re-verified)
Peptides as everything else
The same chemistry underlies products with almost no evidence at all. This site profiles both ends of the spectrum, and the difference between them is not the word "peptide":
| Peptide | What it is | Human evidence | US status |
|---|---|---|---|
| Semaglutide | Engineered GLP-1 analogue | Established evidenceLarge phase 3 RCTs, cardiovascular outcomes trial | FDA-approved (3 indications) |
| PT-141 (bremelanotide) | Cyclic melanocortin agonist | Established evidenceTwo phase 3 RCTs in one population | FDA-approved (1 indication) |
| Collagen peptides | Food-grade protein hydrolysate | Promising evidenceSeveral small RCTs, mostly industry-funded | Food ingredient (GRAS) |
| BPC-157 | Synthetic gastric-derived fragment | Preclinical evidenceNo controlled efficacy trial | Not approved; cannot be lawfully compounded |
What "research peptides" means
Vendors sell BPC-157, TB-500, CJC-1295, ipamorelin, GHK-Cu and even semaglutide and tirzepatide labelled "for research use only" or "not for human consumption". The label is a legal posture, not a regulatory category. The molecules may be the same ones studied in laboratories, but the products are outside any quality system: no one verifies that the vial contains what it says, at the stated amount, without contaminants. Our analysis of certificates of analysis explains why a PDF from the seller does not close that gap.
Regulators have also acted directly on several of these compounds. In 2023 the FDA placed BPC-157, CJC-1295, ipamorelin and others in a category of bulk substances that "raise significant safety risks" and are not eligible for pharmacy compounding[4].
How to use the word from here on
When you see "peptide", mentally replace it with "amino-acid chain" and then ask the questions that matter: which peptide, for which use, with what human evidence, and what regulatory status? Every profile and analysis on this site is built to answer those four questions separately, because collapsing them is how most bad peptide advice starts.
Where to go next
- How to read peptide research without falling for marketing — the study types, the animal-to-human gap, and the tricks.
- FDA-approved, off-label, investigational, and unapproved peptides — the regulatory categories explained.
- Peptide profiles — every peptide we cover, graded.
Frequently asked questions
- Are peptides the same as proteins?
- Chemically they are made of the same building blocks. By convention, chains of up to about 50 amino acids are called peptides and longer chains proteins; the FDA draws its regulatory line at 40.
- Are peptides steroids?
- No. Steroids are lipid-derived molecules built on a four-ring carbon skeleton. Peptides are chains of amino acids. Some peptides (growth hormone secretagogues) are used in doping alongside steroids, which causes the confusion.
- Are all peptides drugs?
- No. Some are approved drugs, some are food ingredients (collagen peptides), some are cosmetics (copper peptides), some are hormones your body makes, and some are unapproved substances sold as "research chemicals".
- Are peptides safe?
- The question has no answer at the category level. Each peptide has its own evidence and safety profile, and unregulated products add product-quality risks on top of whatever the molecule does.
References
Numbered in order of first use. Study type is shown for every source; see our methodology for how we rank evidence.
- 1.
ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin — Guidance for Industry U.S. Food and Drug Administration, 2021.
Regulatory source
Result: FDA defines "peptide" for regulatory purposes as a polymer of 40 or fewer amino acids; larger molecules are proteins regulated as biologics.
↑ back to text - 2.
Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery Nature Reviews Drug Discovery, 2021.
Review
Result: Reviews the >80 approved peptide drugs, their pharmacological strengths and limitations, and development trends.
↑ back to text - 3.
Wilding JPH, Batterham RL, Calanna S, et al.. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) New England Journal of Medicine, 2021.
Randomized controlled trialAdults with overweight or obesity, without diabetesn = 1961
Result: Mean weight loss 14.9% vs 2.4% placebo at 68 weeks.
↑ back to text - 4.
Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (category 2 list) U.S. Food and Drug Administration, 2026.
Regulatory source
Result: Category 2 identifies bulk substances FDA judges to present significant safety risks in compounding. Several popular research peptides were placed there in September 2023; most nominations were later withdrawn by the nominators.
↑ back to text
Review status: Editorially reviewed against primary sources. This article was fact-checked against the primary sources listed in the references by our editorial team, and it has not been reviewed by a licensed clinician. It is educational content, not medical advice. Read our editorial policy and methodology. Spotted an error? Tell us.
